Jump to content

Coagulation: Difference between revisions

From MedLabWiki
No edit summary
No edit summary
Line 133: Line 133:
300ul citrate
300ul citrate


Coagulation Testing
== Coagulation Testing ==
All coagulation testing uses sodium citrate (light blue top) tubes to yield plasma. Centrifuge to separate plasma from platelets, yielding platelet poor plasma (to prevent activation of coagulation).
 
* RT: 4 hours
* Frozen: 2 weeks (-20C) to 6 months (-80C)
 
{| class="wikitable"
{| class="wikitable"
|+
|+
!Test
!What? (Test)
!Test Method
!Why?
!How? (Methodology)
!Causes of Abnormal Results
!Causes of Abnormal Results
!RI
!RI
|-
|-
|PT/INR (Prothrombin Time)
|PT/INR (Prothrombin Time)
|Assess deficiencies or inhibitors of '''extrinsic or common''' pathways
|
|
* Citrated PPP (platelet poor plasma)
* Calcium thromboplastin added to sample (calcium and tissue factor source)
* Calcium thromboplastin added
** Activates coagulation cascade
* Measured optically or mechanically
* Measured optically or mechanically
** Optical: light scattered as fibrin strands form
** Optical: light scattered as fibrin strands form
** Mechanical: magnetic balls oscillates, movement impeded by clot
** Mechanical: magnetic balls oscillates, movement impeded by clot
|
|
|11.5-13.5s
|11.5 - 13.5 s
INR: 0.9-1.2
INR: 0.9 - 1.2
|-
|-
|APTT
|APTT
|Assess deficiencies or inhibitors of '''intrinsic or common''' pathways
|
|
* Citrated PPP mixed with APTT reagent
* APTT reagent added to sample (contains contact activator and phospholipids)
* Activation of factor XII and XI
** Activation of factor XII and XI
* Calcium then added to activate factor IX and VIII
* Calcium then added to activate factor IX and VIII
* Factor X activated, causing cascade to activate Factor II and I, forming fibrin clot
* Factor X activated, causing cascade to activate Factor II and I, forming fibrin clot
|
|
|23-35 s
|23 - 35 s
|-
|-
|Fibrinogen (Clauss Assay)
|Fibrinogen (Clauss Assay)
|Assess fibrinogen activity
|
|
* Clauss assay uses reference plasma samples with known concentrations of fibrinogen
* Clauss assay uses reference plasma samples with known concentrations of fibrinogen
Line 167: Line 176:
* Patient samples can then be run and compared to the curve to determine fibrinogen concentration
* Patient samples can then be run and compared to the curve to determine fibrinogen concentration
|
|
|
|1.5 - 4 g/L
|-
|-
|Thrombin Time
|Thrombin Time
|Assess deficiencies of fibrinogen or the presence of thrombin inhibitors
|
|
* Citrated PPP
* Low concentration of thrombin added to cleave fibrinogen fibrin
* Low concentration of thrombin added to cleave fibrinogen -> fibrin
* Measure time to form fibrin clot
* Measure time to form fibrin clot
|
|Drugs
* Congential fibrinogen deficiencies
* Heparin
* Acquired fibrinogen deficincies
* Direct thrombin inhibitors (dabigatran, apixaban, etc.)
* Unfractionated heparin
Conditions
* Direct thrombin inhibitors (dabigatran, apixaban)
 
*Congenital fibrinogen deficiencies
* Acquired fibrinogen deficiencies
* Increased clot breakdown (e.g., DIC)
|
|
|-
|-
|Unfractionated Heparin/Anti-Xa Assay
|Unfractionated Heparin/Anti-Xa Assay
|
|
|
|
|
Line 187: Line 200:
|-
|-
|Factor Assays
|Factor Assays
|
|
|
|
|
|
|
|}
|}

Revision as of 16:22, 1 February 2025

Factors II, V, VIII, HMWK -> cofactors

Factors II, VII, 9-12, Prekallikrein -> serine proteases

Vitamin K Dependent Factors

  • Serine Proteases
    • Factors II, VII, IX, X
    • Regulatory control proteins C, S, Z
Factor Other Names Pathway(s) Role Location of Synthesis
I Fibrinogen Common
II Prothrombin Common
III Tissue Factor (TF)
IV Ca2+
V Labile factor Common
VII Stable factor Extrinsic
VIII Anti-hemophilic factor Intrinsic
IX Christmas Factor Intrinsic
X Stuart-Prower Factor Common
XI PTA (Plasma Thromboplastin Antecedent) Intrinsic
XII Hageman Factor Intrinsic
XIII Fibrin Stabilizing Factor (FSF) Crosslinks adjacent fibrin strand D-domains to make an insoluble polymer
VWF
HMWK High Molecular Weight

Stages of Hemostasis

  1. Primary hemostasis
  2. Secondary hemostasis
  3. Fibrin clot formation
  4. Coagulation inhibition

Protein Z

  • Z-dependent protease inhibitor (ZPI)
  • Protein Z enhances ZPI activity
    • inhibits factor X and XI

Restoring Blood Flow

  • Fibrinolytic proteins
    • Plasminogen
      • Converted into plasmin by TPA and UPA
      • Plasmin helps restore blood flow
    • TPA
    • UPA

1.85*10^-3 x (100-HCT) x v

300ul citrate

Coagulation Testing

All coagulation testing uses sodium citrate (light blue top) tubes to yield plasma. Centrifuge to separate plasma from platelets, yielding platelet poor plasma (to prevent activation of coagulation).

  • RT: 4 hours
  • Frozen: 2 weeks (-20C) to 6 months (-80C)
What? (Test) Why? How? (Methodology) Causes of Abnormal Results RI
PT/INR (Prothrombin Time) Assess deficiencies or inhibitors of extrinsic or common pathways
  • Calcium thromboplastin added to sample (calcium and tissue factor source)
    • Activates coagulation cascade
  • Measured optically or mechanically
    • Optical: light scattered as fibrin strands form
    • Mechanical: magnetic balls oscillates, movement impeded by clot
11.5 - 13.5 s

INR: 0.9 - 1.2

APTT Assess deficiencies or inhibitors of intrinsic or common pathways
  • APTT reagent added to sample (contains contact activator and phospholipids)
    • Activation of factor XII and XI
  • Calcium then added to activate factor IX and VIII
  • Factor X activated, causing cascade to activate Factor II and I, forming fibrin clot
23 - 35 s
Fibrinogen (Clauss Assay) Assess fibrinogen activity
  • Clauss assay uses reference plasma samples with known concentrations of fibrinogen
  • Run thrombin time (high thrombin concentration) and plot results of concentration vs. time
  • Patient samples can then be run and compared to the curve to determine fibrinogen concentration
1.5 - 4 g/L
Thrombin Time Assess deficiencies of fibrinogen or the presence of thrombin inhibitors
  • Low concentration of thrombin added to cleave fibrinogen → fibrin
  • Measure time to form fibrin clot
Drugs
  • Heparin
  • Direct thrombin inhibitors (dabigatran, apixaban, etc.)

Conditions

  • Congenital fibrinogen deficiencies
  • Acquired fibrinogen deficiencies
  • Increased clot breakdown (e.g., DIC)
Unfractionated Heparin/Anti-Xa Assay
Factor Assays